Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Test Accurately Detects Colon Cancer

By LabMedica International staff writers
Posted on 30 Jan 2012
An innovative multimarker stool DNA test is highly accurate at detecting precancerous polyps and early-stage colorectal cancer (CRC).

The stool DNA test works by finding signature genetic markers in stool samples mailed in by patients and a positive test would be followed by a colonoscopy to remove the polyps and prevent a subsequent cancer from forming.

The screening test was developed in a collaboration between Mayo Clinic (Rochester, MN, USA) and Exact Sciences Inc (Madison, WI, USA). It is highly accurate and significantly more sensitive than other noninvasive tests at detecting precancerous tumors such as adenomas and early-stage cancer. The scientists performed a blinded, multicenter, case-control study using archived stool samples collected in preservative buffer from 252 patients with colorectal cancer (CRC), 133 with adenomas equal to or greater than 1 cm, and 293 individuals with normal colonoscopy results acting as controls. The stool DNA (sDNA) test detects four methylated genes, a mutant form of the Kirsten rat sarcoma viral oncogene (KRAS), and as a reference value the α-actin gene, using quantitative, allele-specific, real-time target and signal amplification; it also quantifies hemoglobin.

The sDNA test identified 85% of patients with CRC and 54% of patients with adenomas equal to or greater than 1 cm with 90% specificity. The test had a high rate of detection for all nonmetastatic stages of CRC, with an aggregate 87% detection rate for CRC stages I-III. Detection rates increased with adenoma size: sensitivity was 64% for polyps larger than 1 cm, 77% for those larger than 2 cm, 86% for those larger than 3 cm, and 92% for those larger than four cm. The stool DNA test detected 87% of curable-stage colorectal cancer in nearly 400 cases. Importantly, detection sensitivity was not affected by tumor location or stage.

The authors concluded that early-stage CRC and large adenomas can be detected throughout the colorectum and with high levels of accuracy by the sDNA test. Neoplasm size, but not anatomical site, affected detection rates. Further studies are needed to validate the findings in a larger population and optimize the sDNA test. Stephen Thibodeau, PhD, a geneticist at Mayo Clinic, said, "These data illustrate the strength of the multimarker stool DNA test to the critical screening targets - precancers and early-stage cancer, and, importantly, this test appears to uniquely represent an accurate noninvasive approach to large polyp detection, which offers the promise of actually preventing cancers from developing." The study was available online since November 2011 in the journal Gastroenterology.

Related Links:
Mayo Clinic
Exact Sciences Inc.



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.